Executive Summary Between 2023 and 2028, an estimated $356 billion in worldwide branded pharmaceutical sales sit exposed to patent expiration. […]

Executive Intelligence Brief Biosimilar development is not generic drug development with more paperwork. It is a $100M-to-$300M scientific undertaking that

Executive Summary Every month, the FDA issues a batch of Tentative Approvals (TAs) for generic drug applications. Most market participants

1. What Excipients Actually Are, and Why the Definition Undersells Them The word ‘excipient’ derives from the Latin excipere, meaning

How European Supplementary Protection Certificates actually work, why their expiry dates keep moving, and what that means for your market

Executive Summary How to win 180-day exclusivity, survive the price erosion curve, and build a future-proof portfolio in a $491B

I. The $300 Billion Opportunity Hiding in Plain Sight The most reliable, legally mandated, and fiscally massive cost-containment event in

The 20-year patent term is the most cited number in pharmaceutical business strategy. It is also, in practice, a fiction.

Part I: The Exclusivity Architecture: What Executives Get Wrong About the 20-Year Rule The number ’20 years’ is the most